Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Conjugated Proteins02:50

Conjugated Proteins

18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Humoral Immune Responses01:36

Humoral Immune Responses

72.5K
Overview
72.5K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

775
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
775

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of a proprietary chlorine-stabilizing surface-coating formulation on healthcare environment disinfection in multidrug-resistant bacteria isolation rooms.

Antimicrobial resistance and infection control·2026
Same author

Acute kidney injury following amikacin therapy: a retrospective cohort study.

The Journal of antimicrobial chemotherapy·2026
Same author

Infective endocarditis treated surgically: correlation between imaging, and surgical findings.

The international journal of cardiovascular imaging·2026
Same author

Cranial nerve neuropathies: a rare manifestation of cat scratch disease.

BMC infectious diseases·2026
Same author

Cat scratch disease encephalitis: New insights into rate, clinical features, and long-term outcomes.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Improving urine culture appropriateness and reducing unnecessary testing through education and feedback in a hospital setting.

BMC infectious diseases·2025

Related Experiment Video

Updated: Jun 23, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K

Hyperimmune Globulins in COVID-19.

Yasmin Maor1,2, Oren Zimhony3,4

  • 1Infectious Disease Unit, E. Wolfson Medical Center, Halochamim 62, 58100, Holon, Israel. yasminm@wmc.gov.il.

Current Topics in Microbiology and Immunology
|June 14, 2024
PubMed
Summary
This summary is machine-generated.

Hyperimmune immunoglobulins (hIG) show promise for treating COVID-19, offering advantages over convalescent plasma. Further research into large-scale production is recommended for future pandemics.

Keywords:
COVID-19Convalescent plasmaHyperimmune globulins

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.7K

Related Experiment Videos

Last Updated: Jun 23, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K
Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.2K
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

7.7K

Area of Science:

  • Immunology
  • Virology
  • Therapeutics

Background:

  • The COVID-19 pandemic necessitated novel therapeutic strategies due to the lack of proven treatments.
  • COVID-19 convalescent plasma (CCP) showed initial promise but had variable efficacy tied to antibody titers.
  • Hyperimmune immunoglobulins (hIG) emerged as a purified alternative derived from CCP.

Purpose of the Study:

  • To evaluate the efficacy and potential of hyperimmune immunoglobulins (hIG) as a COVID-19 therapy.
  • To compare hIG with placebo and CCP, considering factors influencing its effectiveness.
  • To explore advantages of hIG over CCP and future production strategies.

Main Methods:

  • Purification of hIG from CCP units via stringent chromatographic processing.
  • Clinical trials assessing outcomes at day 28 compared to placebo or CCP.
  • Analysis of factors contributing to hIG efficacy variability.

Main Results:

  • hIG likely improved outcomes compared to placebo or CCP at day 28, especially in unvaccinated patients.
  • Efficacy was influenced by assessment timing, hIG dose, patient immunity, and viral variant matching.
  • hIG offers advantages in administration and variant-specific preparations over CCP.

Conclusions:

  • hIG presents a viable therapeutic option for COVID-19, with potential benefits over CCP.
  • Further studies are needed, particularly in immunocompromised and persistently infected patients.
  • Developing infrastructure for large-scale, plasma-independent hIG production is crucial for future pandemic preparedness.